Viyash Scientific files Investor Day 2026 presentation with growth roadmap

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDF

VIYASH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.4%1-day move

₹273.60

prior close

₹266.90

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.2-0.3+1.8+0.6-1.4+1.0+5.6+6.8+7.9+2.3-2.0-4.8——

Up moveDown movePending

AI summary

Viyash Scientific filed its Investor Day 2026 presentation from Mumbai, June 25. Revenue grew from INR 26,807 MN (FY24) to INR 34,203 MN (FY26); EBITDA rose from INR 2,739 MN to INR 7,025 MN. Q4FY26 revenue up 19 percent YoY, EBITDA up 64 percent. Revenue mix led by animal formulations at 45 percent, then API+CDMO and human formulations. 2032 targets: about 1 billion USD revenue, 250 million USD EBITDA, ROCE 25 percent plus. Signed Bio For Life Italy acquisition.

Likely market impact

Clear long-term targets and strong post-merger EBITDA growth may support investor confidence. Pipeline and Italy acquisition give visibility on growth.